Your question
Is this care offer allowed in the US?
Begin by naming the medicine precisely and asking why it is being offered. “Peptide care” is too broad to answer this question on its own.
Does a prescription settle the question?
Under US federal law in September 2026, a prescription medicine can be supplied only after a licensed prescriber writes a prescription.
That person is called the prescriber. Ask for their full name and licence. Then ask whether the medicine itself has approval. A prescription does not answer that question.
What does approval mean here?
Specific drug products and particular uses are reviewed by the US drug agency, the Food and Drug Administration (FDA).
As of September 2026, FDA approval records contain no approved US drug product for BPC-157, ipamorelin, or retatrutide.
As of September 2026, FDA says compounding retatrutide or cagrilintide is forbidden under federal law.
Compounding means making a medicine to order.
Can making medicine to order be allowed?
Compounding prepares medicine to order. In September 2026, FDA says this may fill a care need that approved products cannot address.
In September 2026, federal rules limit making copies of available medicines to order regularly or in large amounts.
Your prescriber must judge that the change made to the medicine prepared to order makes a significant difference for your care.
FDA names examples of needs approved products may not address: inability to swallow tablets, or a dye allergy.
Making the medicine cheaper is not enough to meet that rule.
Ask: “How has this medicine been changed? Why is that difference important in my care?”
Why does the shortage list matter?
As of September 2026, neither semaglutide shots nor tirzepatide shots are on FDA’s list of national drug shortages.
A national shortage listing can allow copies to be made to order that would otherwise be restricted.
One pharmacy running out does not mean FDA has listed a national shortage.
Ask: “Which rule allows this medicine to be made to order for me?”
Does a research label make it treatment?
In warning letters reviewed in September 2026, FDA accused sellers of offering unapproved drugs for use in people despite research labels.
FDA said those sales broke federal law.
A warning letter states the agency’s concerns; it is not a final finding.
Ask for the medicine’s approval record or an explanation of why it can lawfully be made to order. A research label does not answer that question.
What matters here?
Ask who can write the prescription, then ask why this exact medicine can lawfully be supplied to you.